PMID- 35334417
OWN - NLM
STAT- MEDLINE
DCOM- 20220426
LR  - 20230402
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Print)
IS  - 0169-5002 (Linking)
VI  - 166
DP  - 2022 Apr
TI  - Overview of health-related quality of life and toxicity of non-small cell lung 
      cancer patients receiving curative-intent radiotherapy in a real-life setting 
      (the REQUITE study).
PG  - 228-241
LID - S0169-5002(22)00378-6 [pii]
LID - 10.1016/j.lungcan.2022.03.010 [doi]
AB  - OBJECTIVES: Radiotherapy-induced toxicity may negatively impact health-related 
      quality of life (HRQoL). This report investigates the impact of curative-intent 
      radiotherapy on HRQoL and toxicity in early stage and locally-advanced non-small 
      cell lung cancer patients treated with radiotherapy or chemo-radiotherapy 
      enrolled in the observational prospective REQUITE study. MATERIALS AND METHODS: 
      HRQoL was assessed using the European Organisation for Research and Treatment of 
      Cancer QLQ-C30 questionnaire up to 2 years post radiotherapy. Eleven toxicities 
      were scored by clinicians using the Common Terminology Criteria for Adverse 
      Events (CTCAE) version 4. Toxicity scores were calculated by subtracting baseline 
      values. Mixed model analyses were applied to determine statistical significance 
      (p </= 0.01). Meaningful clinical important differences (MCID) were determined for 
      changes in HRQoL. Analysis was performed on the overall data, different 
      radiotherapy techniques, multimodality treatments and disease stages. RESULTS: 
      Data of 510 patients were analysed. There was no significant change in HRQoL or 
      its domains, except for deterioration in cognitive functioning (p = 0.01). 
      Radiotherapy technique had no significant impact on HRQoL. The addition of 
      chemotherapy was significantly associated with HRQoL over time (p <.001). Overall 
      toxicity did not significantly change over time. Acute toxicities of 
      radiation-dermatitis (p =.003), dysphagia (p =.002) and esophagitis (p <.001) 
      peaked at 3 months and decreased thereafter. Pneumonitis initially deteriorated 
      but improved significantly after 12 months (p =.011). A proportion of patients 
      experienced meaningful clinically important improvements and deteriorations in 
      overall HRQoL and its domains. In some patients, pre-treatment symptoms improved 
      gradually. CONCLUSIONS: While overall HRQoL and toxicity did not change over 
      time, some patients improved, whereas others experienced acute 
      radiotherapy-induced toxicities and deteriorated HRQoL, especially physical and 
      cognitive functioning. Patient characteristics, more so than radiotherapy 
      technique and treatment modality, impact post-radiotherapy toxicity and HRQoL 
      outcomes. This stresses the importance of considering the potential impact of 
      radiotherapy on individuals' HRQoL, symptoms and toxicity in treatment 
      decision-making.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Van der Weijst, Lotte
AU  - Van der Weijst L
AD  - Department of Radiation Oncology, Ghent University Hospital and Ghent University, 
      Ghent, Belgium. Electronic address: Lotte.vanderweijst@ugent.be.
FAU - Aguado-Barrera, Miguel E
AU  - Aguado-Barrera ME
AD  - Fundacion Publica Galega de Medicina Xenomica, Grupo de Medicina Xenomica (USC), 
      Santiago de Compostela, Spain.
FAU - Azria, David
AU  - Azria D
AD  - Federation Universitaire d'oncologie radiotherapie d'Occitanie Mediterranee, Univ 
      Montpellier, IRCM Inserm U1194, ICM, Montpellier, France.
FAU - Berkovic, Patrick
AU  - Berkovic P
AD  - Department of radiotherapy-oncology, Leuvens Kanker Instituut, UZ Leuven, Leuven, 
      Belgium.
FAU - Boisselier, Pierre
AU  - Boisselier P
AD  - Federation Universitaire d'oncologie radiotherapie d'Occitanie Mediterranee, Univ 
      Montpellier, IRCM Inserm U1194, ICM, Montpellier, France.
FAU - Briers, Erik
AU  - Briers E
AD  - Patient Advocat, Hasselt, Belgium.
FAU - Bultijnck, Renee
AU  - Bultijnck R
AD  - Department of Radiation Oncology, Ghent University Hospital and Ghent University, 
      Ghent, Belgium; Research Foundation - Flanders (FWO), Brussels, Belgium.
FAU - Calvo-Crespo, Patricia
AU  - Calvo-Crespo P
AD  - Department of Radiation Oncology, Hospital Clinico Universitario de Santiago, 
      SERGAS, Instituto de Investigacion Sanitaria de Santiago de Compostela, Spain.
FAU - Chang-Claude, Jenny
AU  - Chang-Claude J
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany; University Cancer Center Hamburg, University Medical Center 
      Hamburg-Eppendorf, Germany.
FAU - Choudhury, Ananya
AU  - Choudhury A
AD  - Translational Radiobiology Group, Division of Cancer Sciences, University of 
      Manchester, Manchester Academic Health Science Centre, Christie Hospital, United 
      Kingdom.
FAU - Defraene, Gilles
AU  - Defraene G
AD  - Laboratory of Experimental Radiotherapy, Department of Oncology, KULEUVEN, 
      Leuven, Belgium.
FAU - Demontois, Sylvian
AU  - Demontois S
AD  - Federation Universitaire d'oncologie radiotherapie d'Occitanie Mediterranee, Univ 
      Montpellier, IRCM Inserm U1194, ICM, Montpellier, France.
FAU - Dunning, Alison M
AU  - Dunning AM
AD  - Centre for Cancer Genetic Epidemiology, Department of Oncology, University of 
      Cambridge, Strangeways Research Labs, United Kingdom.
FAU - Elliott, Rebecca M
AU  - Elliott RM
AD  - Translational Radiobiology Group, Division of Cancer Sciences, University of 
      Manchester, Manchester Academic Health Science Centre, Christie Hospital, United 
      Kingdom.
FAU - Ennis, Dawn
AU  - Ennis D
AD  - Royal Derby Hospital, Derby DE22 3NE, United Kingdom.
FAU - Faivre-Finn, Corinne
AU  - Faivre-Finn C
AD  - University of Manchester, The Christie NHS Foundation Trust, United Kingdom.
FAU - Franceschini, Marzia
AU  - Franceschini M
AD  - Unit of Radiation Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Gutierrez-Enriquez, Sara
AU  - Gutierrez-Enriquez S
AD  - Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), 
      Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
FAU - Herskind, Carsten
AU  - Herskind C
AD  - Department of Radiation Oncology, Universitatsmedizin Mannheim, Medical Faculty 
      Mannheim, University of Heidelberg, Mannheim, Germany.
FAU - Higginson, Daniel S
AU  - Higginson DS
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, United 
      States.
FAU - Kerns, Sarah L
AU  - Kerns SL
AD  - Departments of Radiation Oncology and Surgery, University of Rochester Medical 
      Center, Rochester, New York, NY, United States.
FAU - Johnson, Kerstie
AU  - Johnson K
AD  - Leicester Cancer Research Centre, University of Leicester, Leicester LE1 7RH, 
      United Kingdom.
FAU - Molla, Meritxell
AU  - Molla M
AD  - Radiation Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron 
      Barcelona Hospital Campus, Barcelona, Spain.
FAU - Lambrecht, Maarten
AU  - Lambrecht M
AD  - Department of radiotherapy-oncology, Leuvens Kanker Instituut, UZ Leuven, Leuven, 
      Belgium.
FAU - Ramos, Monica
AU  - Ramos M
AD  - Radiation Oncology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron 
      Barcelona Hospital Campus, Barcelona, Spain.
FAU - Rancati, Tiziana
AU  - Rancati T
AD  - Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
      Italy.
FAU - Rimner, Andreas
AU  - Rimner A
AD  - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, United 
      States.
FAU - Rosenstein, Barry S
AU  - Rosenstein BS
AD  - Department of Radiation Oncology, Department of Genetics and Genomic Sciences, 
      Icahn School of Medicine at Mount Sinai, New York, United States.
FAU - De Ruysscher, Dirk
AU  - De Ruysscher D
AD  - Department of Radiation Oncology (Maastro), Maastricht University Medical Center, 
      GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands.
FAU - Salem, Ahmed
AU  - Salem A
AD  - University of Manchester, The Christie NHS Foundation Trust, United Kingdom.
FAU - Sangalli, Claudia
AU  - Sangalli C
AD  - Unit of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Seibold, Petra
AU  - Seibold P
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 
      Heidelberg, Germany.
FAU - Sosa-Fajardo, Paloma
AU  - Sosa-Fajardo P
AD  - Department of Radiation Oncology, Hospital Clinico Universitario de Santiago, 
      SERGAS, Instituto de Investigacion Sanitaria de Santiago de Compostela, Spain.
FAU - Sperk, Elena
AU  - Sperk E
AD  - Department of Radiation Oncology, Universitatsmedizin Mannheim, Medical Faculty 
      Mannheim, University of Heidelberg, Mannheim, Germany.
FAU - Stobart, Hilary
AU  - Stobart H
AD  - Independent Cancer Patients' Voice, United Kingdom.
FAU - Summersgill, Holly
AU  - Summersgill H
AD  - Translational Radiobiology Group, Division of Cancer Sciences, University of 
      Manchester, Manchester Academic Health Science Centre, Christie Hospital, United 
      Kingdom.
FAU - Surmont, Veerle
AU  - Surmont V
AD  - Department of Respiratory Medicine, Ghent University Hospital and Ghent 
      University, Ghent, Belgium.
FAU - Symonds, Paul
AU  - Symonds P
AD  - Leicester Cancer Research Centre, University of Leicester, Leicester LE1 7RH, 
      United Kingdom.
FAU - Taboada-Lorenzo, Begona
AU  - Taboada-Lorenzo B
AD  - Department of Radiation Oncology, Hospital Clinico Universitario de Santiago, 
      SERGAS, Instituto de Investigacion Sanitaria de Santiago de Compostela, Spain.
FAU - Talbot, Christopher J
AU  - Talbot CJ
AD  - Leicester Cancer Research Centre, University of Leicester, Leicester LE1 7RH, 
      United Kingdom.
FAU - Valdagni, Riccardo
AU  - Valdagni R
AD  - Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
      Italy; Unit of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei 
      Tumori, Milan, Italy; Dept. of Oncology and Hemato-oncology, Universita degli 
      Studi di Mlano, Milan, Italy.
FAU - Vega, Ana
AU  - Vega A
AD  - Fundacion Publica Galega de Medicina Xenomica, Grupo de Medicina Xenomica (USC), 
      Santiago de Compostela, Spain; Instituto de Investigacion Sanitaria de Santiago 
      de Compostela, Biomedical Network on Rare Diseases (CIBERER), Spain.
FAU - Veldeman, Liv
AU  - Veldeman L
AD  - Department of Radiation Oncology, Ghent University Hospital and Ghent University, 
      Ghent, Belgium.
FAU - Veldwijk, Marlon R
AU  - Veldwijk MR
AD  - Department of Radiation Oncology, Universitatsklinikum Mannheim, Medical Faculty 
      Mannheim, University of Heidelberg, Mannheim, Germany.
FAU - Ward, Tim
AU  - Ward T
AD  - Trustee Pelvic Radiation Disease Association, NCRI CTRad Consumer, United 
      Kingdom.
FAU - Webb, Adam
AU  - Webb A
AD  - Department of Genetics and Genome Biology, University of Leicester, United 
      Kingdom.
FAU - West, Catharine M L
AU  - West CML
AD  - Translational Radiobiology Group, Division of Cancer Sciences, University of 
      Manchester, Manchester Academic Health Science Centre, Christie Hospital, United 
      Kingdom.
CN  - REQUITE Consortium
FAU - Lievens, Yolande
AU  - Lievens Y
AD  - Department of Radiation Oncology, Ghent University Hospital and Ghent University, 
      Ghent, Belgium.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220315
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung/psychology/radiotherapy
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Prospective Studies
MH  - Quality of Life/psychology
MH  - *Radiation Injuries/epidemiology/etiology
MH  - Surveys and Questionnaires
PMC - PMC9698940
MID - NIHMS1834479
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/03/26 06:00
MHDA- 2022/04/27 06:00
PMCR- 2023/04/01
CRDT- 2022/03/25 20:12
PHST- 2021/08/10 00:00 [received]
PHST- 2022/02/08 00:00 [revised]
PHST- 2022/03/08 00:00 [accepted]
PHST- 2022/03/26 06:00 [pubmed]
PHST- 2022/04/27 06:00 [medline]
PHST- 2022/03/25 20:12 [entrez]
PHST- 2023/04/01 00:00 [pmc-release]
AID - S0169-5002(22)00378-6 [pii]
AID - 10.1016/j.lungcan.2022.03.010 [doi]
PST - ppublish
SO  - Lung Cancer. 2022 Apr;166:228-241. doi: 10.1016/j.lungcan.2022.03.010. Epub 2022 
      Mar 15.